Abstract: The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a parenterally-administered medicament for the treatment of cancer.

Abstract: This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30 000.

Abstract: The invention relates to novel fast-disintegrating, or even instant-disintegrating, homogeneous microporous compositions for pharmaceutical, veterinary, food, dietetic or cosmetic use, intended for the oral route or to be applied in contact with the mucous membranes and a method for producing them.

Abstract: The invention relates to a self-adhesive transdermal device for the administration of testosterone and/or at least one of the derivatives thereof, comprising successively at least one support layer, a self-adhesive matrix layer and a detachable protective layer, whereby the matrix layer comprises at least one self-adhesive polymer, at least one formulating adjuvant for the matrix layer, at least one solvent chosen from the group made up of solvents of testosterone or the derivatives thereof and testosterone and/or at least one of the derivatives thereof in an oversaturated solution. The device has excellent testosterone permeation qualities and excellent cutaneous tolerance and adhesion qualities. The invention also relates to a method for the production of said device and the use thereof for a medicament, i.e. within the framework of a testosterone replacement therapy.

Abstract: A pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs.

Abstract: The invention described herein relates to a pharmaceutical composition containing vinorelbine as an active ingredient which is suitable for encapsulation in soft capsules. The liquid oral pharmaceutical composition suitable for a liquid fill composition for a soft capsule dosage form comprises: vinorelbine or a pharmaceutically acceptable salt thereof; ethanol; water; glycerol; and polyethylene glycol. In a preferred embodiment, the tartrate salt form of vinorelbine is used in the composition. The invention also provides for a method of treating cancer comprising orally administering, to a patient in need of treatment thereof, a soft capsule comprising the pharmaceutical composition of the invention.

Abstract: The invention relates to a self-adhesive transdmal device for the administration of testosterone and/or at least one of the derivatives thereof, comprising successively at least one supprt layer, a self-adhesive matrix layer and a detachable protective layer, whereby the matrix layer comprises at least one self-adhesive polymer, at least one formulating adjuvant for the matix layer, at least one solvent chosen from the group made up of solvents of testosterone or the derivatives thereof and testosterone and/or at least one of the derivatives thereof in an oversaturated solution. The device has excellent testosterone permeation qualities and excellent ous tolerance and adhesion qualities. The invention also relates to a method for the production of said device and the use thereof for a mulicament, i.e. within the framework of a testosterone replacement tberapy.

Abstract: The invention described herein relates to a pharmaceutical composition containing vinorelbine as an active ingredient which is suitable for encapsulation in soft capsules. The liquid oral pharmaceutical composition suitable for a liquid fill composition for a soft capsule dosage form comprises: vinorelbine or a pharmaceutically acceptable salt thereof; ethanol; water; glycerol; and polyethylene glycol. In a preferred embodiment, the tartrate salt form of vinorelbine is used in the composition. The invention also provides for a method of treating cancer comprising orally administering, to a patient in need of treatment thereof, a soft capsule comprising the pharmaceutical composition of the invention.

Abstract: Pharmaceutical composition comprising 5 to 20% of an idazoxan salt or of idazoxan hydrate, 10 to 40% of microcrystalline cellulose, 1 to 5% of lubricant, 0.1 to 0.5% of colloidal silica and from 29.5% to 84.8% of lactose, with respect to the total mass.

Abstract: The invention concerns more particularly dodecylthio-phenylacetanilide derivative complexes such as (S)-2?,3?,5?-trimethyl-4?-hydroxy-?-dodecylthio-phenylacetanilide or related derivatives thereof and cyclodextrins.

Abstract: The invention concerns more particularly dodecylthio-phenylacetanilide derivative complexes such as (S)-2′,3′,5′-trimethyl-4′-hydroxy-&agr;-dodecylthio-phenylacetanilide or related derivatives thereof and cyclodextrins.

Abstract: The invention concerns liquid or pasty thixotropic compositions containing an active substance for filling capsules at room temperature. The compositions become fluid by the effect of shearing when they pass through the filling nozzle, then recover their consistency with sufficient intensity and rapidity to prevent, after filling any leak between the two capsule parts. Said compositions are characterized in that their rheological properties are specially adapted for filling and for optimal recovery of consistency. They are preferably in the form of dispersions supporting amphiphilic excipients. Said compositions enable the formulation of active liquid, pasty and even solid substances.

Abstract: The invention concerns a pharmaceutical composition with prolonged release, for oral administration of a single daily dose of 60 to 140 mg of Milnacipran, having a multi-particulate form containing a plurality of microgranules each comprising an active microsphere containing a saccharose and/or starch nucleus of a size between 200 and 2000 &mgr;m and containing 150 to 1000 &mgr;m of Milnacipran and a binding agent, each microgranule being coated with a film having a base of at least one polymer insoluble in water but permeable to physiological liquids, of a thickness between 20 and 100 &mgr;m, the said pharmaceutical composition enabling an in vitro release corresponding to the following pattern: between 10 and 55% of the dose released in 2 hours, between 40 and 75% of the dose released in 4 hours, between 70 and 90% of the dose released in 8 hours, between 80 and 100% of the dose released in 12 hours.

Abstract: The invention concerns a topical pharmaceutical preparation, characterized in that it consists of the combination of an oxan and a pharmaceutically acceptable excipient for transdermal delivery of said oxan.

Abstract: The invention described herein relates to a pharmaceutical composition containing vinorelbine as an active ingredient which is suitable for encapsulation in soft capsules. The liquid oral pharmaceutical composition suitable for a liquid fill composition for a soft capsule dosage form comprises: vinorelbine or a pharmaceutically acceptable salt thereof; ethanol; water; glycerol; and polyethylene glycol. In a preferred embodiment, the tartrate salt form of vinorelbine is used in the composition. The invention also provides for a method of treating cancer comprising orally administering, to a patient in need of treatment thereof, a soft capsule comprising the pharmaceutical composition of the invention.

Abstract: The invention concerns a self-adhesive transdermal device comprising at least two chambers such that the first chamber is a reservoir-type transdermal device (2) and the second chamber is a matrix-type transdermal device (6) located at the periphery of the first chamber. The invention is characterised in that said two devices contain the same active principle.

Abstract: The invention concerns multilayer microspheres containing an acid substance, a basic substance, and a water-soluble isolating agent which, when it dissolves in water, after almost instant effervescence, brings about a homogeneous dispersion of active principal(s) which is present in the acid and basic substances. The invention also concerns a method for preparing such microspheres by rotational granulation on a fluid air bed associated with a system of tangential spraying of the wetting liquid.

Abstract: The present invention relates to a sustained-release tablet, characterized in that it comprises as active principle isosorbide 5-mononitrate (5-ISMN) in the form of a powder having a particle size of 80 .mu.m to 500 .mu.m, in homogeneous dispersion in a hydrophilic matrix based on at least one swelling component and at least one diluent component.

Abstract: The present invention relates to tablets of the type which contain a homogeneous dispersion of an active principle based on salbutamol or on one of its derivatives in a hydrophilic matrix, ensuring:in vitro, long-term release of the active principle, which is constant and independent of pH, over a time interval of about 12 hours,in vivo, uptake kinetics of the active principle by the organism of zero order over a time interval of 6 hours, the said matrix containing at least one swelling agent and a diluent in a weight ratio of swelling agent/diluent lying between 0.2 and 0.6, and being preferably equal to about 0.4.The present invention also covers the process for the preparation of these tablets.